TR201000668T1 - Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati - Google Patents

Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati

Info

Publication number
TR201000668T1
TR201000668T1 TR2010/00668T TR201000668T TR201000668T1 TR 201000668 T1 TR201000668 T1 TR 201000668T1 TR 2010/00668 T TR2010/00668 T TR 2010/00668T TR 201000668 T TR201000668 T TR 201000668T TR 201000668 T1 TR201000668 T1 TR 201000668T1
Authority
TR
Turkey
Prior art keywords
nucleic acid
neoplastic
immunoprophilacy
immunotherapy
polypeptide
Prior art date
Application number
TR2010/00668T
Other languages
English (en)
Inventor
Bedi Atul
Li Shulin
Ravi Rajani
Original Assignee
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Johns Hopkins University filed Critical The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Publication of TR201000668T1 publication Critical patent/TR201000668T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Mevcut buluş, bir antikor/peptid-nükleik asit konjugatının özelliklerinden faydalanarak hedeflenen hücrelerde immün aracılı ve doğrudan ölüm sinyallerinin çapraz aktivasyonunu indükleyen komposizyonları ortaya koyar. Konjugat aynı anda çoklu ölüm sinyalleri mekanizmasını aktive eder.mevcut buluşa ait konjugatın, enfeksiyöz hastalık, neoplastik hastalıklar veya diğer bozuklukların tedavisi veya engellenmesi için immünoterapötik bir tarz olarak kullanılmasına yönelik yöntemler.
TR2010/00668T 2007-07-31 2008-07-31 Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati TR201000668T1 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US789507P 2007-07-31 2007-07-31
US2217308P 2008-01-18 2008-01-18

Publications (1)

Publication Number Publication Date
TR201000668T1 true TR201000668T1 (tr) 2010-06-21

Family

ID=40304902

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/00668T TR201000668T1 (tr) 2007-07-31 2008-07-31 Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati

Country Status (12)

Country Link
US (1) US20090123467A1 (tr)
EP (1) EP2178896A1 (tr)
JP (1) JP2010535248A (tr)
KR (1) KR20100063048A (tr)
CN (1) CN102317303A (tr)
AU (1) AU2008283802A1 (tr)
CA (1) CA2695385A1 (tr)
GB (1) GB2464887A (tr)
MX (1) MX2010001194A (tr)
RU (1) RU2010107199A (tr)
TR (1) TR201000668T1 (tr)
WO (1) WO2009018500A1 (tr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007812B2 (en) 2004-12-22 2011-08-30 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
ES2804472T3 (es) 2005-12-13 2021-02-08 Harvard College Estructuras para trasplante celular
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
CN104873982A (zh) 2007-08-17 2015-09-02 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
WO2010014957A1 (en) 2008-08-01 2010-02-04 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
WO2010043045A1 (en) * 2008-10-17 2010-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
RU2600798C2 (ru) * 2009-04-01 2016-10-27 Юниверсити Оф Майами Композиции вакцин и способы их применения
US20130209514A1 (en) * 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
EP2461828B1 (en) 2009-07-31 2017-06-21 President and Fellows of Harvard College Programming of cells for tolerogenic therapies
JP2013507934A (ja) * 2009-10-16 2013-03-07 ベイラー カレッジ オブ メディスン 遺伝子療法適用のためのスーパーコイル状ミニサークルｄｎａ
SG183273A1 (en) * 2010-02-12 2012-09-27 Solulink Inc Preparation and/or purification of oligonucleotide conjugates
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2540311A4 (en) 2010-02-26 2016-07-06 Univ Nagasaki COMPOSITE BODY FOR RELEASING ANTIGENS OR MEDICAMENTS
US9382366B2 (en) * 2010-06-25 2016-07-05 University Of Massachusetts Protein transduction domains mimics
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
KR102155383B1 (ko) 2010-10-06 2020-09-11 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012079115A1 (en) * 2010-12-14 2012-06-21 Commonwealth Scientific And Industrial Research Organisation Immunostimulatory oligonucleotides
US9814740B2 (en) 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
EP2663367A4 (en) 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF A TOLL-TYPE RECEPTOR AGONIST FOR THE TREATMENT OF CANCER
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2952210A3 (en) * 2011-04-07 2016-03-16 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
EP2701745B1 (en) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
MX2013013801A (es) * 2011-05-26 2013-12-16 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
MX346596B (es) * 2011-05-26 2017-03-23 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CA2870309C (en) 2012-04-16 2024-02-20 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
WO2013173608A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
EP2850189B8 (en) 2012-05-16 2019-01-23 Translate Bio MA, Inc. Compositions and methods for modulating gene expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
EP3858341A1 (en) 2012-11-15 2021-08-04 Endocyte, Inc. Psma ligand-containing conjugates for the treatment of prostate cancer
CN103396996B (zh) * 2013-01-30 2014-12-31 无锡贝瑞康生物科技有限公司 一种携带TGF-βRⅡ和NKG2D基因的NK92细胞株、制备方法及用途
KR20150003617A (ko) * 2013-07-01 2015-01-09 서강대학교산학협력단 바이오 프로세싱 장치
US20150050313A1 (en) * 2013-08-16 2015-02-19 The Regents Of The University Of California Novel immunostimulants and synthesis thereof
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
JP6736464B2 (ja) * 2013-08-29 2020-08-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 細胞透過性コンジュゲート及びその使用の方法
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
WO2015102316A1 (ko) * 2013-12-30 2015-07-09 경희대학교 산학협력단 링커를 통해 연결된 동일한 표적 물질에 결합하는 항체 및 앱타머를 포함하는 집게 분자 및 이의 용도
JP2017502068A (ja) 2014-01-10 2017-01-19 シャンハイ バーディー バイオテック インコーポレイテッド Ｈｅｒ２陽性腫瘍を処置するための化合物及び組成物
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
CA2948054A1 (en) * 2014-04-03 2015-10-08 Augusta University Research Institute, Inc. Methods for enhancing the efficacy of a tumor-directed immune response
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
JP6760919B2 (ja) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド 腫瘍を治療するための抗ｐｄ−ｌ１組み合わせ
CA2994218A1 (en) 2014-07-30 2016-02-04 Cleveland Biolabs, Inc. Flagellin compositons and uses
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
WO2016074580A1 (zh) * 2014-11-14 2016-05-19 中国科学院上海生命科学研究院 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016221305B2 (en) 2015-02-18 2021-05-27 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA2993478A1 (en) * 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
EP3368559A4 (en) * 2015-10-30 2020-01-15 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
JP7366541B2 (ja) * 2016-02-19 2023-10-23 コード バイオセラピューティクス インコーポレイテッド 核酸キャリア及び治療上の使用方法
KR101859683B1 (ko) * 2016-03-17 2018-07-02 서강대학교산학협력단 줄기세포 분화 제어를 위한 바이오몰레트론
EP3235515A1 (en) * 2016-04-21 2017-10-25 Eberhard Karls Universität Tübingen Targeted mrna for in vivo application
CN113813231B (zh) * 2016-07-01 2022-06-21 四川大学 抗菌肽衍生物在制备核酸载体中的用途及核酸载体
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
EP3507308A4 (en) * 2016-09-04 2020-03-18 TargImmune Therapeutics AG CHIMERIC PROTEINS FOR TARGETING DOUBLE-STRANDED RNA
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3554515A4 (en) 2016-12-15 2020-08-26 Duke University B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS
WO2018140831A2 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2018144955A1 (en) * 2017-02-02 2018-08-09 Silverback Therapeutics, Inc. Construct-peptide compositions and methods of use thereof
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
RU2020102453A (ru) 2017-06-23 2021-07-23 Бирди Байофармасьютикалз, Инк. Фармацевтические композиции
CN109453187B (zh) * 2018-09-27 2020-12-29 天津医科大学 具有双重酶敏感特性的抗体核酸药物偶联物及其制备方法和应用
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
CN110129328B (zh) * 2019-04-25 2021-02-09 华中农业大学 ltk基因在制备日本青鳉无背景荧光透明品系中的应用
CN110115764B (zh) * 2019-05-07 2021-10-29 天津大学 一种声控肿瘤高效协同免疫治疗可视化微纳载体系统及其制备方法、应用
CN110124055B (zh) * 2019-05-14 2022-07-08 南京大学 一种靶向pd-l1的抗体-核酸偶联药物及其制备方法和应用
CN114206355A (zh) * 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
CN110609020B (zh) * 2019-08-15 2021-10-01 济南大学 基于回文分子信标检测atp的生物传感器及其制备方法和应用
EP4048689A4 (en) * 2019-10-23 2023-11-01 Cue Biopharma, Inc. T-CELL MODULATING CHIMERIC MOLECULES AND METHOD OF USE THEREOF
US20230227547A1 (en) * 2019-11-12 2023-07-20 Iprogen Biotech Inc. Antibody-payload conjugates with enhanced delivery domain and uses thereof
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113376146A (zh) * 2020-02-25 2021-09-10 上海交通大学 适于生物分子多重检测的检测颗粒及其制备方法与应用
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
CN113018432B (zh) * 2021-03-11 2022-12-13 湖南大学 一种免疫药物的制备方法
KR20230165829A (ko) * 2021-04-02 2023-12-05 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 이중특이적 분자 및 관련 조성물 및 방법
CN114028545A (zh) * 2021-11-30 2022-02-11 中国科学院昆明动物研究所 一种抗病毒感染ll-37-dna复合物及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US7273695B1 (en) * 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5378805A (en) * 1990-08-29 1995-01-03 United States Of America Immunoreactive HTLV-I/II ENV and POL peptides
US7060283B1 (en) * 1992-09-15 2006-06-13 Ortho Diagnostic Systems, Inc. Immunoreactive peptides from Epstein-Barr virus
WO1994027150A1 (en) * 1993-05-10 1994-11-24 Nissui Pharmaceutical Co., Ltd. Method for assaying more than one immunological ligand, and assay reagent and kit therefor
US5596081A (en) * 1994-03-11 1997-01-21 University Of Kentucky Research Foundation Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7038026B2 (en) * 2000-05-26 2006-05-02 Centelion Purification of a triple heli formation with an immobilized oligonucleotide
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
EP1589109B1 (en) * 1996-02-21 2017-04-12 Board of Regents, The University of Texas System VMP-like sequences of pathogenic borrelia
AU4992197A (en) * 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
EP0986572B2 (en) * 1997-06-06 2007-06-13 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
FR2766495B1 (fr) * 1997-07-22 2001-07-13 Pasteur Institut Souche de mycobacterium dont le gene erp est modifie et composition vaccinale la contenant
EP1053355B1 (en) * 1998-02-11 2001-11-14 PE Corporation (NY) Pna and dna conjugates and methods for preparation thereof
EP1067956B1 (en) * 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
EP1700603A3 (en) * 1999-09-25 2007-06-13 Coley Pharmaceutical GmbH Immunostimulatory nucleic acids
EP2292632A3 (en) * 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
CN1309417C (zh) * 2001-02-15 2007-04-11 王荣福 穿细胞肽在产生抗肿瘤免疫力上的用途
US20040109869A1 (en) * 2001-03-19 2004-06-10 Iomai Corporation Transcutaneous immunostimulation
US7189513B2 (en) * 2001-03-23 2007-03-13 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus immunoreactive peptides
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1288244A1 (en) * 2001-08-31 2003-03-05 Asahi Glass Company, Limited Double metal cyanide complex catalyst for ring opening polymerization of alkylene oxide and its production process
AU2002360278A1 (en) * 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
US6942972B2 (en) * 2001-10-24 2005-09-13 Beckman Coulter, Inc. Efficient synthesis of protein-oligonucleotide conjugates
US20070003514A1 (en) * 2002-04-05 2007-01-04 The Regents Of The University Of California Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
CA2483468A1 (en) * 2002-04-24 2003-11-06 Universite Libre De Bruxelles Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process
WO2003091418A2 (en) * 2002-04-26 2003-11-06 Bristol-Myers Squibb Company Novel essential fungal polynucleotides, polypeptides, and methods of use
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US20040204377A1 (en) * 2002-11-26 2004-10-14 University Of Massachusetts Delivery of siRNAs
US7534431B2 (en) * 2003-01-31 2009-05-19 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
US7404950B2 (en) * 2003-02-18 2008-07-29 Baylor College Of Medicine Induced activation in dendritic cell
AT412400B (de) * 2003-05-08 2005-02-25 Mayrhofer Peter Mag Dr Minicircle-herstellung
EP2581093B1 (en) * 2003-06-16 2015-03-18 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
WO2006002438A2 (en) * 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor i (cd64)
US20080051323A1 (en) * 2004-08-21 2008-02-28 Kosak Kenneth M Chloroquine drug compositions and methods for their synthesis
US7196768B2 (en) * 2004-10-26 2007-03-27 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
EP1809671B1 (en) * 2004-11-09 2014-07-16 University Of Southern California CpG/antibody conjugate against cancer
EP1844142B1 (en) * 2005-01-20 2015-08-12 Nature Technology Corporation Vectors and methods for genetic immunization
US7604935B2 (en) * 2005-10-26 2009-10-20 Roche Diagnostics Operations, Inc. Soluble rubella E1 envelope protein variants
EP1790358A1 (en) * 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Protein constructs designed for targeting and lysis of cells
EP1986698A2 (en) * 2006-02-01 2008-11-05 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US20080031887A1 (en) * 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same

Also Published As

Publication number Publication date
CA2695385A1 (en) 2009-02-05
GB2464887A (en) 2010-05-05
WO2009018500A1 (en) 2009-02-05
WO2009018500A8 (en) 2010-03-11
US20090123467A1 (en) 2009-05-14
JP2010535248A (ja) 2010-11-18
KR20100063048A (ko) 2010-06-10
CN102317303A (zh) 2012-01-11
MX2010001194A (es) 2010-07-30
EP2178896A1 (en) 2010-04-28
RU2010107199A (ru) 2011-09-10
GB201003411D0 (en) 2010-04-14
AU2008283802A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
TR201000668T1 (tr) Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
WO2007089871A3 (en) Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2007007173A3 (en) Human anti-madcam antibodies
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX2010001975A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
NZ603829A (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
WO2007068750A3 (en) Immunoglobulins directed against nogo
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals